Everest Medicines Acquires Exclusive Rights to VIS-101 for Serious Eye Disorders
Everest Medicines announced an exclusive license with Visara, Inc. to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.
Collaboration Details
The collaboration marks Everest's expansion into ophthalmology, a high-potential therapeutic area. Under the exclusive license, Everest Medicines will make an upfront payment of US$7 million and reimburse up to RMB24.0 million for prior expenses, with potential future payments of up to US$89 million.
Partnership Background
Visara, Inc. is a subsidiary of NovaBridge Biosciences, listed on the Nasdaq Global Market under the symbol "NBP". This partnership strengthens Everest's late-stage product pipeline and synergies across its core therapeutic portfolio.
Everest Medicines expands into ophthalmology with exclusive license to VIS-101.
Author's summary: Everest Medicines acquires exclusive rights to novel biologic VIS-101.
More News
- U.S. Destroys Another Alleged Narco Boat
- NewJeans to Appeal Label Contract Court Decision
- Stranger Things 5 trailer shows way more than we were ready for
- 2025 NBA Cup TRACKER: Scores, Schedule, Standings
- Humphrey School Students Host First-Ever Minneapolis Mayoral Forum
- DAVIS: With Major Vote Looming, Residency of School Board Members Called Into Question
- Building Smarter, Flying Further: How HP’s Additive Manufacturing Team Is Changing the Way Drones Are Made
- Billie Eilish Calls on Billionaires to Do More for People in Need
- Dean Lewis Shares Statement Following Misconduct Allegations
- City unveils plan for new stage, remodel of Coleman Hawkins Park next spring